Recombinant CD22 (Epratuzumab Biosimilar) antibody

Catalog No. ABIN5668217

This Rabbit Chimeric antibody specifically detects CD22 (Epratuzumab Biosimilar) in BP, FACS and IP. It exhibits reactivity toward Human, Cynomolgus and Rhesus Monkey.

Quick Overview for Recombinant CD22 (Epratuzumab Biosimilar) antibody (ABIN5668217)

Target: CD22 (Epratuzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human, Cynomolgus, Rhesus Monkey

Host: Rabbit

Clonality: Chimeric

Conjugate: This CD22 (Epratuzumab Biosimilar) antibody is un-conjugated

Application: Blocking Peptide (BP), Flow Cytometry (FACS), Immunoprecipitation (IP)

Clone: HL22

Product Details anti-CD22 (Epratuzumab Biosimilar) Antibody

Purpose: Anti-CD22 [hL22 (Epratuzumab)], Rabbit IgG, kappa

Specificity: This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.

Cross-Reactivity: Cynomolgus, Rhesus Monkey

Characteristics:

Original Species of Ab: Human

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Purity: > 98 % as determined by SDS-PAGE

Endotoxin Level: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogen: This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).

Isotype: IgG kappa

Application Details

Application Notes: Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).

Comment:

This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for CD22 (Epratuzumab Biosimilar)

Target: CD22 (Epratuzumab Biosimilar)

Target Type: Biosimilar

Background: Leu14, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14

UniProt: P20273